
First Biosimilar Receives Legal Clearance for US Market
Zarxio (filgrastim-sndz), manufactured by Sandoz as a biosimilar to Amgen's Neupogen, has finally received marketing approval from a federal appeals court.
Sandoz has finally received permission to commercialize its biosimilar filgrastim-sndz (Zarxio), 6 months following regulatory
The progress in this case has been closely watched by payers, patients, and drug manufacturers because biosimilars are forecast to save an estimated $44 billion in US healthcare costs over the next decade.
Read more in
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.